Larimar Therapeutics (LRMR) EBIT: 2014-2020
Historic EBIT for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' EBIT rose 73.16% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.77%. This contributed to the annual value of -$45.7 million for FY2019, which is 25.31% up from last year.
- As of Q1 2020, Larimar Therapeutics' EBIT stood at -$3.6 million, which was up 51.06% from -$7.3 million recorded in Q4 2019.
- Larimar Therapeutics' EBIT's 5-year high stood at -$3.6 million during Q1 2020, with a 5-year trough of -$17.9 million in Q1 2016.
- Moreover, its 3-year median value for EBIT was -$13.3 million (2019), whereas its average is -$12.3 million.
- Its EBIT has fluctuated over the past 5 years, first tumbled by 34.87% in 2016, then skyrocketed by 73.16% in 2020.
- Over the past 5 years, Larimar Therapeutics' EBIT (Quarterly) stood at -$10.5 million in 2016, then decreased by 27.52% to -$13.4 million in 2017, then dropped by 9.98% to -$14.7 million in 2018, then skyrocketed by 50.44% to -$7.3 million in 2019, then soared by 73.16% to -$3.6 million in 2020.
- Its EBIT was -$3.6 million in Q1 2020, compared to -$7.3 million in Q4 2019 and -$12.9 million in Q3 2019.